Diffuse Malignant Mesothelioma

Malignant Mesothelioma brings together the most current diagnostic criteria and treatment plans from the world’s leading experts on this rare but devastating cancer. The first edition was a critical and commercial success and this revision builds on that reputation. The editors have brought together the world’s leading experts to fully explore the latest scientific breakthroughs in carcinogenesis, immunotherapy, potential vaccination strategies, and gene therapy. The clinical aspects of the book are equally strong, with thorough discussion of epidemiology, etiology, different clinical presentations, imaging (including interventional pulmonology), treatment of benign disease, strategies for multimodality treatment of malignant disease. Editors: Harvey I. Pass, M.D, Chief, Thoracic Surgery, New York University, New York, NY; Nicholas Vogelzang, M.D, Director, Nevada Cancer Institute, Las Vegas, NV; University of Chicago, Michele Carbone, M.D., Ph.D, Researcher and Director, Thoracic Oncology Program, Cancer Research Center of Hawaii, Honolulu, HI; and Anne S. Tsao, M.D, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

This volume is the most up-to-date text available on diffuse malignant mesothelioma and includes all the newest imaging modalities, immunohistochemical features, and ever-expanding information on the molecular characteristics of the cancer. In-depth chapters contain fully referenced text as well as detailed tables and images. While the primary audiences for this book are pathologists and pathology residents, the broad examination of diffuse malignant mesothelioma, including its epidemiology, makes this book valuable to radiologists, surgeons, oncologists, and other clinical physicians and their residents as well. Written by experts in the field, Diffuse Malignant Mesothelioma is a concise yet comprehensive resource for clinicians involved in the management of one of the most widely recognized and feared cancers in the world.

"This volume of the Advances in Surgical Pathology Series is a concise, updated review of the pathological characteristics of mesothelioma. It emphasizes the histologic correlation, clinical management, and treatment of mesothelioma. It features current and emerging concepts in the field, which includes recognition of precursor mesothelial lesions, the role of molecular biology in the diagnosis and prognosis of mesothelioma, the interface between the clinician and the surgical pathologist, and the legal implications in relation to disease attributibility to asbestos and other factors. The book provides a resource for the timely updates in knowledge that are necessary for daily practice, for current credentialing, and for the self-assessment modules for recertification (MOC)."--Provided by publisher.

• Only up-to-date title in the market • Current topic with significant media coverage • Internationally relevant, the use of asbestos and its consequences is a global problem • This title aids in pathological diagnosis which is very difficult • Contributors are experts from France, UK, USA, Australia and Canada • Plentiful, colored illustrations complete the text • Target group exceeds pathologists: The diagnosis is evidence for medico-legal purposes, which makes the book invaluable to members of legal profession specializing in this disease

Advances in Surgical Pathology: Mesothelioma, a volume in the Advances in Surgical Pathology series, features chapters on current and impending changes in the field with an emphasis on practical issues, recent developments, and emerging concepts. Created as a quick review, this volume delivers a concise, updated review of the pathological characteristics of mesothelioma—emphasizing the histologic correlation, clinical management, and treatment of the disease. Timely content features include recognition of precursor mesothelial lesions, the role of molecular biology in the diagnosis and prognosis of mesothelioma, the interface between the clinician and the surgical pathologist, and the legal implications of attributing disease origin to asbestos and other factors. The book provides a resource for the periodic updates in knowledge required for daily practice, for current credentialing, and for the self-assessment modules for recertification.

This issue of Thoracic Surgery Clinics, guest edited by Dr. Bryan M. Burt, is devoted to Malignant Pleural Mesothelioma. Dr. Burt has assembled expert authors to review the following topics: Biomarkers for the Diagnosis and Monitoring of Malignant Pleural Mesothelioma; Taken Together: Effective Multimodal Approaches for Malignant Pleural Mesothelioma; Pleurectomy/Decortication for Malignant Pleural Mesothelioma; Preoperative Identification of Benefit from Surgery for Malignant Pleural Mesothelioma; The Role of Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma; The Molecular Basis of Malignant Pleural Mesothelioma; Radiation Therapy for Malignant Pleural Mesothelioma; The Staging of Malignant Pleural Mesothelioma; Intraoperative Adjuncts for Malignant Pleural Mesothelioma: The Fourth Dimension; The Pathology of Malignant Pleural Mesothelioma; and more!

This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease’s biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.